immune thrombocytopenia

Immune Drivers in Autoimmune Cytopenias Inform Patient Care

Understanding immune drivers in autoimmune cytopenias, discussed at EHA 2026, offers insights into targeted therapies and improved patient management.

Caplacizumab Improves iTTP Outcomes in Real-World Settings

Real-world data presented at EHA 2026 confirm caplacizumab's efficacy in immune-mediated thrombotic thrombocytopenic purpura (iTTP), reducing refractory disease and mortality.

Rare Conditions: EHA 2026 Highlights Diagnostic Challenges

EHA 2026 session 'The Sherlock Holmes Approach' addressed diagnostic delays in rare haematological conditions, emphasizing systematic clinical reasoning.